Clinical trials
Active, not recruiting Phase 2 Hodgkin Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2009 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 4 |
| 2021 | 2 |
| 2023 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| City of Hope Medical Center | 6 |
| St. Jude Children's Research Hospital | 5 |
| M.D. Anderson Cancer Center | 2 |
| Dana-Farber Cancer Institute | 1 |
| Divaya Bhutani | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 1 |
| Tessa Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hodgkin Disease | 23 |
| Lymphoma, Non-Hodgkin | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 |
| Myelodysplastic Syndromes | 6 |
| Leukemia, Myeloid, Acute | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Leukemia, Myeloid, Accelerated Phase | 3 |
| Leukemia, Myeloid, Chronic-Phase | 3 |
| Multiple Myeloma | 3 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.